Eruptive nevi and hair depigmentation related to regorafenib

Regorafenib (Stivarga®) is a new orally available multikinase inhibitor that targets several protein kinases involved in angiogenesis (VEGFR1-3, TIE2), oncogenesis (c-KIT, RET, RAF1, wild-type BRAF and mutated BRAFV600) and maintenance of the tumor microenvironment (PDGF-β, FGFR-1). It has been shown to improve overall or progression-free survival in patients with colorectal cancer and gastrointestinal stromal tumors, respectively [1, 2]. Drug-related toxicity occurs in the majority of patients, [...]